Moderna Inc. (NASDAQ: MRNA) is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 months. What may surprise investors is that the Moderna stock is down approximately 60% over the last five years. That means the stock has given back all the gains it made when the company’s COVID-19 vaccine entered the market, and then some.
One reason for Moderna's sharp fall is the overall sentiment surrounding vaccines in general and mRNA (messenger RNA) technology in particular.
